Tag Archives: ML7710

Modulight Spotlights: LASER-SHARP RESEARCH – August 2024

                    Modulight Spotlights: LASER-SHARP RESEARCH – August 2024 This month’s research highlight goes to Hirofumi Hanaoka and the team at Kansai Medical University, Japan. They developed a new laser fiber and method for illumination of narrow cavities, such as esophagus. With typical laser fibers, it is difficult to precisely illuminate target tumor in a narrow space at an oblique angle, since there is not enough space for fiber bending. The new lateral (side) emitting laser fiber was developed and evaluated for near-infrared photoimmunotherapy, which combines light, Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2024

 Modulight Spotlights: LASER-SHARP RESEARCH – July 2024 Exciting new findings in prostate cancer research were reported by Xinning Wang and team at Case Western University, Comprehensive Cancer Center. Prostate cancer is the most common cancer among men and despite typically good prognosis, is a leading cause of cancer-related death. In the new study, the team combined chemotherapy with a novel light-activated, theranostic agent to enable targeted imaging and treatment of prostate cancer. Using ML7710 laser at 672 nm for activation of the drug, they were Continue reading →

Comparative study of immune response to local tumor destruction modalities in a murine breast cancer model

Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman  Published in: Frontiers in Oncology Authors: Sadna Budhu, Kwanghee Kim, Wesley Yip, Stephen La Rosa, Sylvia Jebiwott, Liqun Cai, Aliya Holland, Jasmine Thomas, Dina Preise, Alex Somma, Benjamin Gordon, Avigdor Scherz, Jedd D. Wolchok, Joseph Erinjeri, Taha Merghoub, Jonathan A. Coleman Three forms of localized tumor destruction (radiation therapy, vascular targeted PDT and cryoablation) were compared for their efficacy in evoking local and systemic immune responses. This has potential to improve effectiveness of immunotherapy in non-responding patients (cold tumors) by attracting T cells to the Continue reading →

Near‐infrared photoimmunotherapy targeting PD‐L1: Improved efficacy by preconditioning the tumor microenvironment

Published in: Cancer Science Authors: Fuyuki F. Inagaki, Makoto Kano, Aki Furusawa, Takuya Kato, Ryuhei Okada, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Science Authors: Fuyuki F. Inagaki, Makoto Kano, Aki Furusawa, Takuya Kato, Ryuhei Okada, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi In this study, the efficacy of PD-L1-targeted NIR-PIT (photoimmunotherapy) with ML7710 was assessed in immune-competent tumor mouse models. PIT showed a significant therapeutic effect on the tumor models with high PD-L1 expression. Furthermore, it induced an abscopal effect on distant tumors and long-term immunological memory. Combination with interferon-gamma improved the treatment efficacy by increasing PD-L1 expression leading to more Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2024

 Modulight Spotlights: LASER-SHARP RESEARCH – April 2024 First-in-human, phase 1 clinical trial results with ML7710 have been published in a renowned journal Radiology by Timothy Baran and team at University of Rochester Medical Center. The trial investigated treatment of deep tissue abscesses using photodynamic therapy with methylene blue and ML7710 laser. Abscesses are painful collection of pus, usually caused by a bacterial infection. Standard treatment is abscess drainage and antibiotics, however treatment responses vary widely and are linked to prolonged hospital stay, costs, and patient discomfort, as well as increasing concerns for antibiotic-resistance. The trial in 18 Continue reading →

Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer

Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) that targets Nectin-4, has shown promising results in the treatment of bladder cancer. The study investigated use of Nectin-4 targeting photoimmunotherapy in preclinical bladder cancer models. ML7710 was used as light source for activating the therapy in vitro and in vivo.   Read the article here

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →

Photoimmuno-antimicrobial therapy for Staphylococcus aureus implant infection

Published in: PLoS One Authors: Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H. A. Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C. H. van der Wal  Published in: PLoS One Authors: Bruce van Dijk, Sabrina Oliveira, J. Fred F. Hooning van Duyvenbode, F. Ruben H. A. Nurmohamed, Vida Mashayekhi, Irati Beltrán Hernández, Jos van Strijp, Lisanne de Vor, Piet C. Aerts, H. Charles Vogely, Harrie Weinans, Bart C. H. van der Wal Photoimmuno-antimicrobial therapy (PIAT) was develop to treat implant infections that cause high morbidity and mortality worldwide. Antibody targeting Wall Teichoic Acid surface components of both S. aureus and its biofilm was conjugated to a photosensitizer IRDye700DX and used as Continue reading →

ML7710 for photoactivated treatment of lung cancer

Deadliest cancer Precision with photoactivation Photoimmunotherapy with ML7710 offers a clinical therapeutic option for NSCLC patients even with advanced disease stage. Besides laser light, this therapy involves photoactivated drug, which can be activated precisely at the tumor site with laser fibers, hence minimizing drug effects to healthy tissues. Smaller invasiveness compared to surgery can enable patients to stay less time recovering at the hospital. It can also be repeated if needed multiple times without cumulating toxicities, unlike radiation therapy. Some previously inoperable tumors can decrease Continue reading →Deadliest cancer Lung cancer is the leading cause of cancer deaths worldwide, with more than 2.2 million cases and 1.8 million deaths each year [1]. Lung cancer can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with the latter accounting for about 85% of all lung cancer cases. NSCL is usually less sensitive to chemo- and radiotherapy and in many cases tumor cannot be removed surgically or has spread from lungs to distant sites at the time Continue reading →

Automated drug detection and dynamic measurement prioritization with medical laser platform

Published in: SPIE BIOS 2024 Authors: Henri Auvinen, Lassi Luokkanen, Zoe Ylöniemi, Natalia Leinonen, Ana Colucci, Petteri Uusimaa  Published in: SPIE BIOS 2024 Authors: Henri Auvinen, Lassi Luokkanen, Zoe Ylöniemi, Natalia Leinonen, Ana Colucci, Petteri Uusimaa Monitoring treatment through spectral data enables adjusting treatment in real-time for each patient separately, in line with the trend for personalized medicine. Modulight ML7710 laser can simultaneously measure spectral data from up to 8 different locations in tumor tissue. The laser with this optical monitoring feature is currently being tested in glioblastoma trials in Germany where patients receive photoimmunotherapy and treatment is tailored through spectral monitoring of Continue reading →